Lopez LR, Miller CM, Jeyachandran JN, Li C, Simpson KW, Arthur JC. Heterogeneity among clinical intestinal escherichia coli isolates upon acquired streptomycin resistance. Microbiol Spectr. 2023 Jun 15;11(3):e035022. doi: 10.1128/spectrum.03500-22
Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch DA. Erratum for Earnshaw et al., Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Oct 26;10(5):e0303122. doi: 10.1128/spectrum.03031-22
Earnshaw S, McDade C, Bryan A, Ines M, Micallef C, Sung A, Enoch D. Real-world financial and clinical impact of diagnostic-driven and empirical-treatment strategies in high-risk immunocompromised patients with suspected aspergillus infection in the United Kingdom. Microbiol Spectr. 2022 Jun 29;10(3):e0042522. doi: 10.1128/spectrum.00425-22
Hiligsmann M, Dellaert BG, Dirksen CD, Watson V, Bours S, Goemaere S, Reginster JY, Roux C, McGowan B, Silke C, Whelan B, Diez-Perez A, Torres E, Papadakis G, Rizzoli R, Cooper C, Pearson G, Boonen A. Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. Rheumatology (Oxford). 2017 Jul 1;56(7):1167-76. doi: 10.1093/rheumatology/kex071
Hifinger M, Hiligsmann M, Ramiro S, Severens JL, Fautrel B, Watson V, Boonen A. Patient's preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists. Rheumatology (Oxford). 2017 Jan;56(1):68-76. doi: 10.1093/rheumatology/kew328
Keenan A-M, McKenna SP, Doward LC, Conaghan PC, Emery P, Tennant A. OAQoL: development and preliminary validation of a needs-based quality of life measure for osteoarthritis. Poster presented at the American College of Rheumatology 2007 Annual Scientific Meeting; April 2007. Chicago, IL. [abstract] Rheumatology (Oxford). 2007; 46:162-3.